Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Elongator acetyltransferase complex subunit 4 (ELP4) is a key component of the six-subunit Elongator complex, a histone acetyltransferase complex evolutionarily conserved in eukaryotes[1][3][5]. ELP4 contributes to multiple cellular functions, including histone acetylation and tRNA modification, which are important for transcriptional elongation and mRNA decoding[1][3][4][5][8]. ELP4 links together other subunits of the Elongator complex, facilitating stability and enzymatic activity. Dysfunction of ELP4, such as through genetic polymorphisms or deletions, has been implicated in several neurodevelopmental disorders (particularly Rolandic epilepsy, language delays, and autism), as well as certain ocular malformations through disruption of the adjacent PAX6 regulatory landscape[1]. There are no known direct drug interactions or common use as a therapeutic target; its primary interest is in disease genetics and rare neurodevelopmental syndromes[1][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Elongator acetyltransferase complex subunit 4 (ELP4).